» Articles » PMID: 11112663

Hereditary Nonpolyposis Colorectal Cancer in 95 Families: Differences and Similarities Between Mutation-positive and Mutation-negative Kindreds

Overview
Journal Am J Hum Genet
Publisher Cell Press
Specialty Genetics
Date 2000 Dec 12
PMID 11112663
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) describes the condition of a disparate group of families that have in common a predisposition to colorectal cancer in the absence of a premalignant phenotype. The genetic basis of this disease has been linked to mutations in genes associated with DNA mismatch repair. A large proportion of families harbor changes in one of two genes, hMSH2 and hMLH1. Approximately 35% of families in which the diagnosis is based on the Amsterdam criteria do not appear to harbor mutations in DNA-mismatch-repair genes. In this report we present data from a large series of families with HNPCC and indicate that there are subtle differences between families that harbor germline changes in hMSH2 and families that harbor hMLH1 mutations. Furthermore, there are differences between the mutation-positive group (hMSH2 and hMLH1 combined) of families and the mutation-negative group of families. The major findings identified in this study focus primarily on the extracolonic disease profile observed between the mutation-positive families and the mutation-negative families. Breast cancer was not significantly overrepresented in the hMSH2 mutation-positive group but was overrepresented in the hMLH1 mutation-positive group and in the mutation-negative group. Prostate cancer was not overrepresented in the mutation-positive groups but was overrepresented in the mutation-negative group. In age at diagnosis of colorectal cancer, there was no difference between the hMSH2 mutation-positive group and the hMLH1 mutation-positive group, but there was a significant difference between these two groups and the mutation-negative group.

Citing Articles

Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with Germline Pathogenic Variants in the and Genes.

Ndou L, Chambuso R, Algar U, Boutall A, Goldberg P, Ramesar R Biomedicines. 2025; 12(12.

PMID: 39767815 PMC: 11672899. DOI: 10.3390/biomedicines12122906.


Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.

Bucksch K, Zachariae S, Aretz S, Buttner R, Holinski-Feder E, Holzapfel S BMC Cancer. 2020; 20(1):460.

PMID: 32448342 PMC: 7245918. DOI: 10.1186/s12885-020-06926-x.


Does breast carcinoma belong to the Lynch syndrome tumor spectrum? - Somatic mutational profiles vs. ovarian and colorectal carcinomas.

Porkka N, Olkinuora A, Kuopio T, Ahtiainen M, Eldfors S, Almusa H Oncotarget. 2020; 11(14):1244-1256.

PMID: 32292574 PMC: 7147090. DOI: 10.18632/oncotarget.27538.


Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.

Yoo J, Lee G, Kim J, Lee S, Chae H, Han E Ann Lab Med. 2019; 40(2):148-154.

PMID: 31650731 PMC: 6822011. DOI: 10.3343/alm.2020.40.2.148.


Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients.

Mori G, Orena B, Cultrera I, Barbieri G, Albertini A, Ranzani G Front Microbiol. 2019; 10:1746.

PMID: 31417532 PMC: 6682596. DOI: 10.3389/fmicb.2019.01746.


References
1.
Vasen H, Wijnen J . Clinical implications of genetic testing of hereditary nonpolyposis colorectal cancer. Cytogenet Cell Genet. 1999; 86(2):136-9. DOI: 10.1159/000015366. View

2.
Buerstedde J, Alday P, Torhorst J, Weber W, Muller H, Scott R . Detection of new mutations in six out of 10 Swiss HNPCC families by genomic sequencing of the hMSH2 and hMLH1 genes. J Med Genet. 1995; 32(11):909-12. PMC: 1051749. DOI: 10.1136/jmg.32.11.909. View

3.
Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

4.
Itoh H, Houlston R, Harocopos C, Slack J . Risk of cancer death in first-degree relatives of patients with hereditary non-polyposis cancer syndrome (Lynch type II): a study of 130 kindreds in the United Kingdom. Br J Surg. 1990; 77(12):1367-70. DOI: 10.1002/bjs.1800771216. View

5.
Watson P, Lynch H . Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993; 71(3):677-85. DOI: 10.1002/1097-0142(19930201)71:3<677::aid-cncr2820710305>3.0.co;2-#. View